Novartis AG Asset Resilience Ratio

Latest as of March 2026: 0.08%

Novartis AG asset resilience ratio. Novartis AG (NOVN) has an Asset Resilience Ratio of 0.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NOVN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CHF100.30 Million

≈ $126.81 Million USD Cash + Short-term Investments

Total Assets

CHF118.89 Billion

≈ $150.31 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Novartis AG (1998–2025)

Asset resilience ratio of Novartis AG from 1998 to 2025. This chart shows how Novartis AG's Asset Resilience Ratio has changed over time. Read Novartis AG total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Novartis AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Novartis AG.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF100.30 Million	0.08%
Total Liquid Assets	CHF100.30 Million	0.08%

Asset Resilience Insights

Limited Liquidity: Novartis AG maintains only 0.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Novartis AG Industry Peers by Asset Resilience Ratio

Compare Novartis AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Virbac SA PA:VIRP	Drug Manufacturers - General	0.23%
AstraZeneca PLC LSE:AZN	Drug Manufacturers - General	0.06%
Zhejiang Int'L Group Co Ltd SHE:000411	Drug Manufacturers - General	0.00%
GuangYuYuan Chinese Herbal Medicine Co Ltd SHG:600771	Drug Manufacturers - General	1.97%
Hubei Guangji Pharmaceutical Co Ltd SHE:000952	Drug Manufacturers - General	5.37%
Firebrick Pharma Ltd AU:FRE	Drug Manufacturers - General	0.29%
Eli Lilly and Company SA:LILY34	Drug Manufacturers - General	6.46%
Pfizer Inc SA:PFIZ34	Drug Manufacturers - General	5.33%

Novartis AG Asset Resilience Ratio by Year (1998–2025)

Novartis AG asset resilience ratio by year from 1998 to 2025. The table below shows the annual Asset Resilience Ratio data for Novartis AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	7.80%	CHF9.01 Billion ≈ $11.39 Billion	CHF115.49 Billion ≈ $146.01 Billion	-2.73pp
2024-12-31	10.53%	CHF10.77 Billion ≈ $13.61 Billion	CHF102.25 Billion ≈ $129.27 Billion	-0.23pp
2023-12-31	10.76%	CHF10.76 Billion ≈ $13.60 Billion	CHF99.94 Billion ≈ $126.36 Billion	-2.64pp
2022-12-31	13.40%	CHF15.74 Billion ≈ $19.90 Billion	CHF117.45 Billion ≈ $148.49 Billion	-5.35pp
2021-12-31	18.75%	CHF24.72 Billion ≈ $31.25 Billion	CHF131.79 Billion ≈ $166.62 Billion	+12.85pp
2020-12-31	5.90%	CHF7.54 Billion ≈ $9.54 Billion	CHF127.78 Billion ≈ $161.55 Billion	-0.84pp
2019-12-31	6.75%	CHF7.99 Billion ≈ $10.10 Billion	CHF118.37 Billion ≈ $149.65 Billion	-2.08pp
2018-12-31	8.82%	CHF12.84 Billion ≈ $16.24 Billion	CHF145.56 Billion ≈ $184.03 Billion	+3.93pp
2017-12-31	4.90%	CHF6.51 Billion ≈ $8.24 Billion	CHF133.08 Billion ≈ $168.25 Billion	+0.39pp
2016-12-31	4.51%	CHF5.87 Billion ≈ $7.41 Billion	CHF130.12 Billion ≈ $164.51 Billion	+3.92pp
2015-12-31	0.59%	CHF773.00 Million ≈ $977.28 Million	CHF131.56 Billion ≈ $166.32 Billion	-0.08pp
2014-12-31	0.67%	CHF839.00 Million ≈ $1.06 Billion	CHF125.39 Billion ≈ $158.52 Billion	-1.34pp
2013-12-31	2.01%	CHF2.54 Billion ≈ $3.20 Billion	CHF126.25 Billion ≈ $159.62 Billion	-0.06pp
2012-12-31	2.07%	CHF2.57 Billion ≈ $3.25 Billion	CHF124.19 Billion ≈ $157.01 Billion	+0.90pp
2011-12-31	1.16%	CHF1.37 Billion ≈ $1.73 Billion	CHF117.50 Billion ≈ $148.55 Billion	-1.12pp
2010-12-31	2.28%	CHF2.81 Billion ≈ $3.56 Billion	CHF123.32 Billion ≈ $155.91 Billion	-12.96pp
2009-12-31	15.24%	CHF14.55 Billion ≈ $18.40 Billion	CHF95.50 Billion ≈ $120.74 Billion	+10.03pp
2008-12-31	5.21%	CHF4.08 Billion ≈ $5.16 Billion	CHF78.30 Billion ≈ $98.99 Billion	-5.18pp
2007-12-31	10.39%	CHF7.84 Billion ≈ $9.91 Billion	CHF75.45 Billion ≈ $95.39 Billion	+4.30pp
2006-12-31	6.09%	CHF4.14 Billion ≈ $5.23 Billion	CHF68.01 Billion ≈ $85.98 Billion	-1.90pp
2005-12-31	7.99%	CHF4.61 Billion ≈ $5.83 Billion	CHF57.73 Billion ≈ $72.99 Billion	-6.89pp
2004-12-31	14.88%	CHF7.81 Billion ≈ $9.87 Billion	CHF52.49 Billion ≈ $66.36 Billion	-0.56pp
2003-12-31	15.44%	CHF7.61 Billion ≈ $9.62 Billion	CHF49.32 Billion ≈ $62.35 Billion	+0.46pp
2002-12-31	14.98%	CHF6.74 Billion ≈ $8.53 Billion	CHF45.02 Billion ≈ $56.92 Billion	-1.04pp
2001-12-31	16.02%	CHF6.46 Billion ≈ $8.16 Billion	CHF40.30 Billion ≈ $50.96 Billion	-4.12pp
2000-12-31	20.14%	CHF7.26 Billion ≈ $9.18 Billion	CHF36.06 Billion ≈ $45.59 Billion	+4.81pp
1999-12-31	15.33%	CHF6.31 Billion ≈ $7.98 Billion	CHF41.14 Billion ≈ $52.02 Billion	+1.96pp
1998-12-31	13.37%	CHF5.46 Billion ≈ $6.91 Billion	CHF40.86 Billion ≈ $51.66 Billion	--

pp = percentage points

About Novartis AG

SW:NOVN Switzerland Drug Manufacturers - General

Market Cap

$317.27 Billion

CHF250.95 Billion CHF

Market Cap Rank

#92 Global

#3 in Switzerland

Share Price

CHF131.52

Change (1 day)

-1.69%

52-Week Range

CHF100.42 - CHF133.78

All Time High

CHF133.78